Forward March: Push Continues for Immunotherapy in Prostate Cancer
September 20, 2016 – Aimee Swartz
Creating a Diversion: Life After Cystectomy for Bladder Cancer
September 22, 2016 – Leah K. Lawrence
A Sign of the Times: The Changing Treatment Landscape for Advanced Kidney Cancer
September 23, 2016 – Marijke Vroomen Durning, RN
Hard to Hear: Cisplatin Can Cause Hearing Loss for Men With Testicular Cancer
September 23, 2016 – Karen Bruno
From Rags to Riches: Bladder Cancer Research Rife With New Approaches
September 27, 2016 – Arlene Weintraub
On the Side: An Overview of Prostate Cancer Treatment Side Effects
September 27, 2016 – Beth Fand Incollingo
Currently Viewing
Honing in on Bladder Cancer: Key Facts
September 28, 2016 – Arlene Weintraub and CURE staff
Prioritizing Clinical Trials Led to New Therapies for Kidney Cancer
September 23, 2016 – Debu Tripathy, M.D.
Another Reason for Excitement About Cancer Immunotherapy
September 23, 2016 – Mike Hennessy, Sr.
Hormonal Therapy for Prostate Cancer: A Closer Look
September 29, 2016
Prostate Cancer Screening: Where Do We Stand?
September 29, 2016
Q & A With Olympian Scott Hamilton: Turning Cancer Upside Down
September 29, 2016 – Laura Panjwani

Honing in on Bladder Cancer: Key Facts

CURE gathered some need-to-know facts about bladder cancer, the sixth most common cancer.
BY Arlene Weintraub and CURE staff
PUBLISHED September 28, 2016
Bladder cancer is the sixth most common cancer overall, but it is the third most prevalent form of the disease in men, according to the National Cancer Institute.

• More than 76,000 new cases of the disease will be diagnosed this year, about 75 percent of which will occur in men.

• The average age at diagnosis is 73, and roughly 16,000 patients die each year from the disease. Aging is one of the major risk factors for the disease, though it has also been linked with tobacco use, family history and exposure to chemicals in certain industrial products.

• The most common type of bladder cancer is urothelial carcinoma, which can originate anywhere in the urinary tract, including the kidneys and the ureters that connect them to the bladder.

• Bladder cancer is referred to either as “muscle-invasive,” meaning it has invaded the thick muscle along the walls of the organs, or “non–muscleinvasive.” Muscle-invasive bladder cancer has a high chance of spreading to other organs.

• Prior to the rise of immunotherapy a few years ago, the standard of care in bladder cancer hadn’t changed much and consisted largely of surgery, chemotherapy and radiation. Chemotherapy is typically given in combinations that include such drugs as gemcitabine/cisplatin or methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), but responses, if seen at all, tend to be brief.

• The five-year survival rate for bladder cancer that has spread to other parts of the body, stage 4, is 15 percent, according to the American Cancer Society.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Bladder Cancer CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In